Claims for Patent: 12,115,254
✉ Email this page to a colleague
Summary for Patent: 12,115,254
| Title: | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
| Abstract: | Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy. |
| Inventor(s): | Thomas B. Ottoboni, Han Han |
| Assignee: | Heron Therapeutics LLC |
| Application Number: | US18/408,486 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,115,254 |
| Patent Claims: |
1. An injectable pharmaceutical emulsion, comprising: about 0.7-0.8 wt % aprepitant; an emulsifier; an oil; a co-surfactant; and water, wherein the ratio of the emulsifier to aprepitant ranges from about 20:1 to 25:1 (wt/wt %). 2. The emulsion of claim 1, wherein the emulsifier is a phospholipid. 3. The emulsion of claim 2, wherein the phospholipid is present in the emulsion at about 16 wt/wt %. 4. The emulsion of claim 2, wherein the phospholipid is present in the emulsion at about 17 wt/wt %. 5. The emulsion of claim 1, wherein the emulsifier is an egg lecithin. 6. The emulsion of claim 5, wherein the egg lecithin is present in the emulsion at about 16 wt/wt %. 7. The emulsion of claim 5, wherein the egg lecithin is present in the emulsion at about 17 wt/wt %. 8. The emulsion of claim 1, wherein the oil is selected from the group consisting of coconut oil, olive oil, soybean oil, safflower oil, triglycerides, octyl and decyl glycerate, ethyl oleate, glyceryl linoleate, ethyl linoleate, glyceryl oleate, cholesteryl oleate, cholesteryl linoleate, and mixtures thereof. 9. The emulsion of claim 8, wherein the oil is present at a concentration of about 9 wt/wt % to 10 wt/wt %. 10. The emulsion of claim 1, wherein the co-surfactant comprises an alcohol. 11. The emulsion of claim 10, wherein the alcohol is present in the emulsion at less than 10 wt/wt %. 12. The emulsion of claim 10, wherein the co-surfactant is ethanol. 13. The emulsion of claim 1, further comprising an osmotic agent. 14. The emulsion of claim 13, wherein the osmotic agent is selected from the group consisting of glycerol, sorbitol, xylitol, mannitol, glucose, trehalose, maltose, sucrose, raffinose, lactose, dextran, polyethylene glycol, or propylene glycol. 15. The emulsion of claim 14, wherein the osmotic agent is present at a concentration of about 3 wt/wt % to 8 wt/wt %. 16. The emulsion of claim 1, further comprising a pH modifier. 17. The emulsion of claim 16, wherein the pH modifier is oleic acid or a salt thereof. 18. The emulsion of claim 1, wherein the emulsifier is egg lecithin. 19. The emulsion of claim 1, wherein the co-surfactant is ethanol. 20. The emulsion of claim 1, further comprising sucrose. 21. The emulsion of claim 1, further comprising sodium oleate. 22. An injectable pharmaceutical emulsion, comprising: about 0.7-0.8 wt % aprepitant; an emulsifier; an oil; a co-surfactant; and water, wherein the ratio of the emulsifier to aprepitant ranges about 23:1 (wt/wt %). 23. The emulsion of claim 22, wherein the emulsifier is a phospholipid. 24. The emulsion of claim 23, wherein the phospholipid is selected from the group consisting of egg phospholipids and soy phospholipids. 25. The emulsion of claim 22, wherein the oil is selected from the group consisting of coconut oil, olive oil, soybean oil, safflower oil, triglycerides, octyl and decyl glycerate, ethyl oleate, glyceryl linoleate, ethyl linoleate, glyceryl oleate, cholesteryl oleate, cholesteryl linoleate, and mixtures thereof. 26. The emulsion of claim 22, wherein the co-surfactant comprises an alcohol present in the emulsion at less than 10 wt/wt %. 27. An injectable pharmaceutical emulsion, comprising: about 0.7-0.8 wt % aprepitant; an emulsifier; an oil; a co-surfactant; and water, wherein the ratio of the emulsifier to aprepitant ranges about 24:1 (wt/wt %). 28. The emulsion of claim 27, wherein the emulsifier is a phospholipid. 29. The emulsion of claim 27, wherein the phospholipid is selected from the group consisting of egg phospholipids and soy phospholipids. 30. The emulsion of claim 27, wherein the oil is selected from the group consisting of coconut oil, olive oil, soybean oil, safflower oil, triglycerides, octyl and decyl glycerate, ethyl oleate, glyceryl linoleate, ethyl linoleate, glyceryl oleate, cholesteryl oleate, cholesteryl linoleate, and mixtures thereof. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
